Anthony M Joshua

Anthony M Joshua

UNVERIFIED PROFILE

Are you Anthony M Joshua?   Register this Author

Register author
Anthony M Joshua

Anthony M Joshua

Publications by authors named "Anthony M Joshua"

Are you Anthony M Joshua?   Register this Author

90Publications

13124Reads

22Profile Views

Developing a pan-cancer research autopsy programme.

J Clin Pathol 2019 Oct 1;72(10):689-695. Epub 2019 Jul 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2019-205874DOI Listing
October 2019

Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary center.

Asia Pac J Clin Oncol 2019 Aug 22;15(4):257-261. Epub 2019 Apr 22.

Kinghorn Cancer Centre, St. Vincent's Hospital, Darlinghurst, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13148DOI Listing
August 2019

Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking.

Anal Chem 2019 Aug 8;91(15):9348-9355. Epub 2019 Jul 8.

Institute of Biomaterials and Biomedical Engineering , University of Toronto , 144 College Street , Toronto , Ontario M5S 3M2 , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.analchem.9b01697DOI Listing
August 2019

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

N Engl J Med 2019 07 2;381(2):121-131. Epub 2019 Jun 2.

From Monash University (I.D.D., M.F., D.W.P.), Eastern Health (I.D.D.), Australian Urology Associates (M.F.), Monash Health (D.W.P.), and the Peter MacCallum Cancer Centre and the University of Melbourne (S.K.S., S.G.W.), Melbourne, VIC, the National Health and Medical Research Council Clinical Trials Centre, University of Sydney (A.J.M., M.R.S., X.C., W.E.H., E.T., S.Y., A.Y.Z.), the Chris O'Brien Lifehouse (M.R.S., L.G.H., A.Y.Z.), the University of Sydney (L.G.H., G.M.), Royal Prince Alfred Hospital (L.G.H.), Kinghorn Cancer Centre, St. Vincent's Hospital, and Garvan Institute of Medical Research (A.M.J.), Macquarie University (A.Y.Z.), and Western Sydney University (R.R.Z.), Sydney, Concord Cancer Centre, Concord Repatriation General Hospital, Concord, NSW (M.R.S.), Port Macquarie Base Hospital and Mid North Coast Cancer Institute Port Macquarie, Port Macquarie, NSW (S.B.), Sydney Adventist Hospital, Wahroonga, NSW (G.M.), the ANZUP Cancer Trials Group, Camperdown, NSW (M.M.), the Adelaide Cancer Centre and the University of Adelaide (F.P.) and the Royal Adelaide Hospital (T.H.T.), Adelaide, SA, and Orange Health Service, Central West Cancer Care Centre, Orange, NSW (R.R.Z.) - all in Australia; BC Cancer and the University of British Columbia, Vancouver (K.N.C.), the Cross Cancer Institute and the University of Alberta, Edmonton (S.A.N.), Canadian Cancer Trials Group, Queen's University (W.P., F.V.-B.), and the Kingston Health Sciences Center (F.V.-B.), Kingston, ON, and the University of Ottawa and the Ottawa Hospital Research Institute, Ottawa (M.N.R.) - all in Canada; Guy's and St. Thomas' NHS Foundation Trust Biomedical Research Centre, Cancer Research UK and King's College London, and Sarah Cannon Research UK, London (S.C.), and the Royal Cornwall Hospital, Truro (A. Thomson) - all in the United Kingdom; Auckland City Hospital, Auckland (N.J.L.), and the Waikato District Health Board, Hamilton (A. Tan) - both in New Zealand; Cancer Trials Ireland (J.M., R.M.), Mater Misericordiae University Hospital (J.M.), and St. Vincent's University Hospital and University College Dublin (R.M.D.) - all in Dublin; and Dana-Farber Cancer Institute and Harvard Medical School (C.J.S.) - both in Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1903835DOI Listing
July 2019

Therapeutic implications of germline genetic findings in cancer.

Nat Rev Clin Oncol 2019 06;16(6):386-396

Cancer Division, Garvan Institute of Medical Research, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0179-3DOI Listing
June 2019

A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial.

Br J Cancer 2019 Jun 20;120(12):1113-1119. Epub 2019 May 20.

Department of Medical Oncology and Haematology Princess Margaret Cancer Centre, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0474-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738062PMC
June 2019

Oncogenic signaling in uveal melanoma.

Pigment Cell Melanoma Res 2018 11 23;31(6):661-672. Epub 2018 May 23.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12708DOI Listing
November 2018

Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients.

Clin Cancer Res 2018 07 3;24(14):3317-3324. Epub 2018 Apr 3.

The Krembil Family Epigenetics Laboratory, The Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-0101DOI Listing
July 2018

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 06 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6270
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6270DOI Listing
June 2018

Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer.

Eur Urol 2018 05 20;73(5):736-737. Epub 2017 Nov 20.

Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, Australia; Garvan Institute of Medical Research, Sydney, Australia; Faculty of Medicine, University of New South Wales, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.11.005DOI Listing
May 2018

Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.

Urol Oncol 2018 May 15;36(5):240.e13-240.e20. Epub 2018 Feb 15.

Uro-Oncology Research Unit, Department of Surgery, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439183001
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2018.01.011DOI Listing
May 2018

A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.

Invest New Drugs 2018 04 18;36(2):278-287. Epub 2017 Dec 18.

Division of Medical Oncology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0553-xDOI Listing
April 2018

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

J Clin Oncol 2018 04 12;36(12):1232-1239. Epub 2018 Mar 12.

Richard D. Carvajal and Gary K. Schwartz, Columbia University Medical Center; Paul B. Chapman and Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center, New York, NY; Sophie Piperno-Neumann and Manuel J. Rodrigues, Institut Curie, Paris; Lauris Gastaud, Centre Antoine-Lacassagne, Nice, France; Ellen Kapiteijn, Leiden University Medical Center, Leiden, the Netherlands; Stephen Frank, Hebrew University Hadassah Medical School - The Sharett Institute of Oncology, Jerusalem; Jacob Schachter, Sheba Medical Center at Tel Hashomer, and Tel-Aviv University Medical School, Tel Aviv, Israel; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Josep M. Piulats, Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Veronique Cocquyt, Ghent University Hospital, Ghent, Belgium; Bartosz Chmielowski, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; T.R. Jeffry Evans, University of Glasgow, Glasgow; Delyth Clemett, Shirley Spratt, Susan Lovick, and Elaine Kilgour, AstraZeneca, Macclesfield; Dana Ghiorghiu and Gabriella Mariani, AstraZeneca, Cambridge; Paul Nathan, Mt Vernon Cancer Centre, Northwood, United Kingdom; Gerald Linette, Washington University School of Medicine, St Louis, MO; Carola Berking, University Hospital of Munich, Munich, Germany; Peter Barker, AstraZeneca, Gaithersburg, MD; and Zhongwu Lai, AstraZeneca, Waltham, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.1090DOI Listing
April 2018

A randomized phase II trial of geriatric assessment and management for older cancer patients.

Support Care Cancer 2018 01 25;26(1):109-117. Epub 2017 Jul 25.

Department of Medicine and Institute of Health Policy, Management, and Evaluation, University Health Network and University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-017-3820-7DOI Listing
January 2018

AR Signaling and the PI3K Pathway in Prostate Cancer.

Cancers (Basel) 2017 Apr 15;9(4). Epub 2017 Apr 15.

Kinghorn Cancer Centre, St Vincent's Hospital, 370 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers9040034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406709PMC
April 2017

AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.

J Urol 2017 01 17;197(1):135-142. Epub 2016 Jul 17.

Vancouver Prostate Centre, University of British Columbia, British Columbia, Vancouver, Canada; British Columbia Cancer Agency, British Columbia, Vancouver, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2016.06.094DOI Listing
January 2017

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol 2016 12 31;34(34):4102-4109. Epub 2016 Oct 31.

Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.2477
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.2477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562434PMC
December 2016

Understanding the role of new systemic agents in the treatment of prostate cancer.

BJU Int 2016 10 6;118 Suppl 3:8-13. Epub 2016 Oct 6.

Austin Health, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.13633DOI Listing
October 2016

The Utility of Serum CA9 for Prognostication in Prostate Cancer.

Anticancer Res 2016 09;36(9):4489-92

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.10994DOI Listing
September 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J Clin Oncol 2016 05 7;34(13):1510-7. Epub 2016 Mar 7.

F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Richard Kefford, Westmead Hospital, Melanoma Institute Australia, and Macquarie University; Peter Hersey, University of Sydney, Sydney, Australia; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; Adil Daud, University of California San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; Caroline Robert, Gustave-Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; Tara C. Gangadhar, Abramson Cancer Center, Philadelphia, PA; Anthony M. Joshua, Princess Margaret Hospital, Toronto, Ontario, Canada; Roxana Dronca, Mayo Clinic, Rochester, MN; Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S. Peter Kang, Scot Ebbinghaus, and Andrea Perrone, Merck, Kenilworth, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547PMC
May 2016

18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study.

Clin Nucl Med 2016 Mar;41(3):189-93

From the *Department of Nuclear Medicine, Hamilton Health Sciences and St. Joseph's Healthcare Hamilton, McMaster University, Hamilton; †Department of Planning and Regional Programs, Planning Unit, Cancer Care Ontario; ‡Department of Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto; §Department of Clinical Programs, Cancer Imaging Program, Cancer Care Ontario; and ∥Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000000996DOI Listing
March 2016

A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.

J Geriatr Oncol 2016 Mar 4;7(2):81-9. Epub 2016 Feb 4.

Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2016.01.003DOI Listing
March 2016

Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.

Prostate 2016 Feb 2;76(2):235-42. Epub 2015 Nov 2.

Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23117DOI Listing
February 2016

Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma.

Oncol Lett 2016 Feb 31;11(2):1581-1585. Epub 2015 Dec 31.

Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2015.4069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734313PMC
February 2016

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.

J Transl Med 2016 Jan 13;14:12. Epub 2016 Jan 13.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, 610 University Ave, Toronto, ON, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-015-0747-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712499PMC
January 2016

Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.

Clin Genitourin Cancer 2015 Aug 7;13(4):e229-e233. Epub 2015 Feb 7.

Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.02.001DOI Listing
August 2015

A phase 2 study of tremelimumab in patients with advanced uveal melanoma.

Melanoma Res 2015 Aug;25(4):342-7

aDepartment of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario bDepartment of Medical Oncology, Tom Baker Cancer Centre, Calgary cDepartment of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta dDepartment of Medical Oncology, Royal Victoria Hospital, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000175DOI Listing
August 2015

Pembrolizumab.

J Immunother Cancer 2015 18;3:36. Epub 2015 Aug 18.

Department of Medical Oncology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0078-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539882PMC
August 2015

Increased treatment-related toxicity subsequent to an anti-PD-1 agent.

Curr Oncol 2015 Aug;22(4):e320-2

Department of Medical Oncology (GU/Melanoma), Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Ontario M5G 2M9,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.22.2418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530830PMC
August 2015

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Eur Urol 2015 Mar 31;67(3):441-7. Epub 2014 Jan 31.

Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2014.01.030DOI Listing
March 2015

Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.

J Geriatr Oncol 2015 Jan 7;6(1):23-8. Epub 2014 Oct 7.

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2014.09.183DOI Listing
January 2015

Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma.

J Immunother Cancer 2014 16;2(1):41. Epub 2014 Dec 16.

University of Toronto Department of Ophthalmology and Vision Sciences, University Health Network/Toronto Western Hospital, 399 Bathurst Street, 6 East Room 415, Toronto, Ontario M5T 2S8 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-014-0041-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266968PMC
December 2014

Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone.

Prostate 2014 Oct 11;74(14):1462-4. Epub 2014 Aug 11.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.22861DOI Listing
October 2014

Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.

Eur J Cancer 2014 Sep 16;50(14):2399-407. Epub 2014 Jul 16.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.06.004DOI Listing
September 2014

Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review.

Endocr Pract 2014 Aug;20(8):e145-50

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4158/EP14093.CRDOI Listing
August 2014

New treatments for metastatic melanoma.

CMAJ 2014 Jul 18;186(10):754-60. Epub 2014 Feb 18.

The Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ont.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1503/cmaj.130989DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081198PMC
July 2014

The changing landscape in metastatic castration-resistant prostate cancer.

Curr Opin Support Palliat Care 2013 Sep;7(3):243-8

Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SPC.0b013e328362ffefDOI Listing
September 2013

TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.

Clin Cancer Res 2013 Sep 5;19(18):5202-9. Epub 2013 Aug 5.

Authors' Affiliations: Departments of Radiation Oncology, Medical Biophysics, Medical Oncology, Laboratory Medicine and Pathology and Biostatistics, University of Toronto; Radiation Medicine Program, Princess Margaret Hospital, University Health Network; Informatics and Bio-Computing Platform, Ontario Institute for Cancer Research, Toronto, Ontario; Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre; Laboratory for Advanced Genome Analysis - Vancouver Prostate Centre, Vancouver, British Columbia; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, Maryland; Division of Urology, University of Montreal Health Center, Montreal, Quebec; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario; and Department of Pathology and Laboratory Medicine and Oncology, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1049DOI Listing
September 2013

Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

Can Urol Assoc J 2013 Jan-Feb;7(1-2):E74-81

Division of Medical Oncology, Princess Margaret Hospital/University of Toronto, Toronto, ON;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650799PMC
May 2013

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.

Mod Pathol 2013 Mar 28;26(3):435-47. Epub 2012 Sep 28.

Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2012.162DOI Listing
March 2013

PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.

Clin Cancer Res 2012 Feb 23;18(4):1015-27. Epub 2011 Nov 23.

Ontario Cancer Institute/Princess Margaret Hospital (University Health Network), University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378487PMC
February 2012

Prostate cancer as a model system for genetic diversity in tumors.

Adv Cancer Res 2011 ;112:183-216

Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-387688-1.00007-7DOI Listing
January 2012

Renal cell carcinoma bone metastases: clinical advances.

Ther Adv Med Oncol 2010 Mar;2(2):75-83

Princess Margaret Hospital, Medical Oncology, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1758834009358417
Publisher Site
http://dx.doi.org/10.1177/1758834009358417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126010PMC
March 2010

Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.

J Clin Endocrinol Metab 2009 Jan 11;94(1):5-9. Epub 2008 Nov 11.

Department of Medical Oncology, Princess Margaret Hospital, University Health Network, 610 University Avenue, M5G 2M9 Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.
Publisher Site
http://dx.doi.org/10.1210/jc.2008-1836DOI Listing
January 2009

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Mod Pathol 2008 Dec 23;21(12):1451-60. Epub 2008 May 23.

Division of Applied Molecular Oncology, Ontario Cancer Institute, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2008.96DOI Listing
December 2008

Web-based resources for clinical bioinformatics.

Methods Mol Med 2008 ;141:309-29

Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
June 2008

Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma.

BMC Cancer 2006 Oct 5;6:237. Epub 2006 Oct 5.

Department of Pediatrics, Instituto de Oncologia Pediátrica (IOP-GRAACC), Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo 04023-062, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-6-237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1609181PMC
October 2006

Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias.

Cancer Genet Cytogenet 2006 Sep;169(2):128-37

Applied Molecular Oncology, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, 610 University Ave., Room 9-721, Toronto, Ontario, M5G 2M9 Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2006.04.003DOI Listing
September 2006

Advances in the adjuvant treatment of colorectal cancer.

ANZ J Surg 2006 May;76(5):373-80

Department of Medical Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1445-2197.2006.03726.x
Publisher Site
http://dx.doi.org/10.1111/j.1445-2197.2006.03726.xDOI Listing
May 2006

Humor and oncology.

J Clin Oncol 2005 Jan;23(3):645-8

Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.09.064DOI Listing
January 2005